Poop pills vs. superbugs: can a fecal transplant beat resistant gut bacteria?

NCT ID NCT04759001

Recruiting now Disease control Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether a fecal transplant from a healthy donor can clear carbapenem-resistant Enterobacteriaceae (CRE) from the gut of carriers. Fifty-two adults with CRE in their gut will be randomly assigned to receive either a real fecal transplant or a placebo via colonoscopy. Researchers will check rectal swabs over three months to see if the bacteria are gone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fecal microbiota transplant (FMT) from healthy donors
What this could lead to: If it works, this could offer a way to clear dangerous drug-resistant bacteria from the gut, lowering the risk of serious infections.
What could go wrong: This is an early-phase trial with only 52 participants. Previous studies have shown mixed results, and the treatment may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENTEROBACTERIACEAE INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Enterobacteriaceae Infections

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENTEROBACTERIACEAE INFECTIONS MULTI-ANTIBIOTIC RESISTANCE

Contacts and locations

Locations

Digestive Disease Center, Fondazione Policlinico Univesitario A. Gemelli IRCCS
RECRUITING

Rome, 00168, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.